Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score.
Improving and targeting nicotine replacement therapy (NRT) are cost-effective strategies for reducing adverse health consequences for smokers. Treatment studies document the efficacy of precessation NRT and support important roles for level of nicotine dependence and precessation smoking reduction in successful quitting. However, prior work has not identified the optimal precessation dose or means for personalizing NRT. Genome-wide association has identified groups of genomic markers associated with successful quitting, allowing us to develop a v1.0 "quit-success" genotype score. We now report influences of v1.0 quit-success genotype score, level of dependence and precessation smoking reduction in a smoking cessation trial that examined effects of 21 versus 42 mg/24 h precessation NRT. Four hundred seventy-nine smokers were randomized to 21 or 42 mg NRT, initiated 2 wks prior to target quit dates. We monitored self-reported abstinence and end-expired air carbon monoxide (CO). Genotyping used Affymetrix arrays (Santa Clara, CA, USA). The primary outcome was 10-wk continuous smoking abstinence. NRT dose, level of nicotine dependence and genotype scores displayed significant interactive effects on successful quitting. Successful abstinence also was predicted by CO reductions during precessation NRT. These results document ways in which smoking cessation strategies can be personalized based on levels of nicotine dependence, genotype scores and CO monitoring. These assessments, taken together, can help match most smokers with optimal NRT doses and help rapidly identify some who may be better treated using other methods.
Rose
Jed E
JE
Department of Psychiatry and Center for Nicotine and Smoking Cessation Research, Duke University, Durham, North Carolina 27705, USA. rose0003@mc.duke.edu
Behm
Frédérique M
FM
Drgon
Tomas
T
Johnson
Catherine
C
Uhl
George R
GR
D000279:Administration, Cutaneous; D000328:Adult; D002248:Carbon Monoxide / Q000032:analysis; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D055106:Genome-Wide Association Study; D005838:Genotype; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009538:Nicotine / Q000008:administration & dosage*; D020641:Polymorphism, Single Nucleotide; D057285:Precision Medicine / Q000379:methods*; D016540:Smoking Cessation / Q000379:methods*; D014029:Tobacco Use Disorder / Q000188:drug therapy* / Q000235:genetics*
D003692:Delayed-Action Preparations; D009538:Nicotine; D002248:Carbon Monoxide